Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Amer M Zeidan,Gary J Schiller,Tara L Lin,Pamela S Becker,Prapti A Patel,Eunice S Wang,Alexander I Spira,Michaela L Tsai,Maya Ridinger,Peter J Croucher,Mark Erlander,Sandra L Silberman

doi:10.1182/blood-2019-126262

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Amer M Zeidan, Gary J Schiller + Show 10 more

Open Access

https://doi.org/10.1182/blood-2019-126262

Copy DOI

Journal: Blood	Publication Date: Nov 13, 2019
Citations: 2

Affiliation: Yale Cancer Center, University of California, Los Angeles, University of Kansas, University of Washington, Fred Hutch Cancer Center, The University of Texas Southwestern Medical Center, Roswell Park Cancer Institute, Virginia Cancer Specialists, Minnesota Oncology

#Research Funding #Advisory Role + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.